amyloid-beta peptide 40/42 in plasma

From Aaushi
Jump to navigation Jump to search


Clinical significance

* authors suggest plasma Abeta40/42 may be used to identify people at risk of cognitive decline [2.3]

* it is difficult to reconcile this with comments in ref[1]


More general terms

Additional terms



  1. 1.0 1.1 1.2 Nakamura A, Kaneko N, Villemagne VL et al High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature. 2018 Feb 8;554(7691):249-254 PMID:
  2. 2.0 2.1 Giudici KV, de Souto Barreto P, Guyonnet S et al Assessment of Plasma Amyloid-beta42/40 and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Netw Open. 2020;3(12):e2028634 PMID:
  3. Pereira JB et al. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain 2021 Jun 2; [e-pub]. PMID:
  4. 4.0 4.1 Janelidze S, Teunissen CE, Zetterberg H et al Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease. JAMA Neurol. Published online September 20, 2021. PMID:
  5. 5.0 5.1 Dark HE, Paterson C, Daya GN et al Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk. Ann Neurol. 2023. Oct 6. PMID: